This October 2026 edition supersedes USDM’s October 2022 white paper. The updated 26-page guide addresses FDA’s final CSA guidance and its February 2026 QMSR update, with expanded coverage of cloud services, AI workflows, supplier assurance, digital evidence, and continuous monitoring.
Modern assurance for cloud platforms, automation, and regulated AI
Software changes faster than traditional validation cycles. Quality, IT, and validation teams need a risk-based way to establish confidence in the features that matter most—and maintain that confidence as platforms, models, and workflows evolve.
Computer Software Assurance & AI Governance Guidance explains how to connect intended use, process risk, testing, supplier evidence, and ongoing oversight. Written by David Blewitt, VP of AI Governance and Digital Trust at USDM Life Sciences, it brings CSA and AI governance into one practical review.
What you will learn
- Understand the 2026 regulatory context: distinguish FDA’s final CSA guidance from the earlier draft and understand its alignment with QMSR and ISO 13485.
- Right-size assurance: evaluate intended use and process risk at the feature and workflow level, including human-reviewed and closed-loop AI.
- Build defensible digital evidence: select scripted, unscripted, or hybrid methods and use system-generated records where appropriate.
- Clarify supplier responsibilities: assess cloud and AI vendors while retaining accountability for your configuration, intended use, and controls.
- Put the guidance into practice: follow a five-step transition roadmap that connects CSV procedures, quality processes, and AI governance.
Inside the revised edition
- Regulatory status and modern assurance — page 3: FDA’s final guidance, the February 2026 update, and the boundary between production/QMS software and medical device software functions.
- Evaluating risk across applications, features, and AI workflows — page 7: intended use, process risk, and effective human oversight.
- Making the transition — page 22: a five-step roadmap, reported implementation examples, and how USDM supports adoption.
Get the 2026 Edition (26-page PDF)
Who should read it
Validation, Quality Assurance, Regulatory Affairs, IT, and AI Governance leaders in medical device, pharmaceutical, biotechnology, and CRO/CMO organizations deploying software, cloud platforms, or AI in production or quality management.
FDA’s CSA guidance applies to software used in medical device production and quality management systems. It does not cover design verification and validation of Software in a Medical Device (SiMD) or Software as a Medical Device (SaMD). Pharmaceutical and biologic drug organizations apply related risk-based principles through GAMP 5 and their applicable GMP requirements.
Keep assurance focused on evidence
The paper explains how audit trails, automated test logs, supplier evidence, and ongoing monitoring can support confidence in software. Human review reduces AI risk only when the review is enforced and effective in practice. USDM’s risk matrix and AI implementation recommendations are practitioner guidance, not additional FDA mandates.
About the 2026 update
Does this replace the previous USDM CSA white paper?
Yes. The October 2026 edition explicitly supersedes the October 2022 edition and expands the discussion to cloud platforms, automation, and AI governance.
Is FDA’s CSA guidance still a draft?
No. As described in this edition, FDA issued final guidance on September 24, 2025 and updated it on February 3, 2026 to align with QMSR. The guidance does not create new statutory requirements.
Does supplier evidence replace our own assurance responsibilities?
No. Qualified supplier evidence provides a baseline. Your organization remains accountable for its intended use, configuration, integrations, risk assessment, and appropriate assurance activities.
Download the 2026 edition
Use the form to request the 26-page Computer Software Assurance & AI Governance Guidance white paper. For implementation support, explore USDM’s CSA services, Cloud Assurance, and AI governance and compliance.